BioNTech

BioNTech SE (ˈbaɪɒnˌtek) is a German biotechnology company dedicated to the creation of active immunotherapies for treatments of serious diseases.

BioNTech headquarters in An der Goldgrube street, Mainz

BioNTech SE

Company type	Public (SE)
Traded as	NASDAQ: BNTX
ISIN	US09075V1026
Industry	Biotechnology
Founded	2008; 17 years ago (2008)
Founders	Uğur Şahin Özlem Türeci Christoph Huber Andreas Strüngmann Thomas Strüngmann Michael Motschmann Helmut Jeggle
Headquarters	Mainz , Germany
Number of locations	8 (2022)
Area served	Worldwide
Key people	Uğur Şahin (CEO) Özlem Türeci (CMO) Sean Marett (CBO, CCO) Sierk Poetting (CFO, COO) Ryan Richardson (CSO)
Products	BNT162b2
Services	Immunotherapy
Revenue	€17.3 billion (2022)
Operating income	€12.6 billion (2022)
Net income	€9.43 billion (2022)
Total assets	€23.3 billion (2022)
Total equity	€20.1 billion (2022)
Number of employees	4,530 (2022)
Website	biontech.com
Footnotes / references Biontech FY 2022 report[1]

It researches drugs based on messenger RNA (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases.^[2] In 2020, the company started developing the BNT162b2 vaccine against SARS-CoV-2 with Pfizer^[3] and Fosun.^[4][5] In late 2020 BioNTech successfully developed, together with Pfizer, the RNA vaccine called BNT162b2 against COVID-19. The company said, it's vaccine efficacy was 95%. On 2 December 2020, the United Kingdom government gave permission to use BNT162b2 vaccinations in the country.^[6] Later in December 2020 USA,^[7] Canada^[8] and the EU^[9] also gave permission to use the BioNTech vaccine.